Paul Hasler

1. Personal Data

Date of birth: 8th June, 1956 Nationality: Swiss, British

Address: aarReha

Badstrasse 55

5116 Schinznach Bad

Switzerland

Telephone +4156 463 86 21, Mobile +4179 448 13 34

Email paul.hasler@aarreha.ch, private paul-hasler@gmx.net

2. Current position

Medical Director, Attending Physician, aarReha, Schinznach Bad, Switzerland.

3. Education, Diplomas

2021 Certificate Medical Councilor (Vertrauensarzt), Swiss Society of Medical

Councilors.

2014 Certificate Expert in Insurance Medicine (Zertifizierter Gutachter SIM), Swiss

Society for Insurance Medicine.

2004 Professor of Rheumatology, Medical Faculty of the University of Basel.

1994 Swiss Board Certification in General Internal Medicine and Rheumatology.

Promotion to Doctor of Medicine at the University of Bern.

1983 ECFMG certification.

1982 Physician’s degree, University of Bern.

4. Work Experience

2022 July to October and from April 2024 Medical Director and Physician-in-Chief

,Musculoskeletal and Internal Medical/Oncologic Rehabilitation, aarReha,

Schinznach Bad, Switzerland.

2002-2022 Physician-in-Chief, Division of Rheumatology, Medical University Department,

Kantonsspital Aarau, Aarau, Switzerland.

2011-2021 President, Research Council, Kantonsspital Aarau (in-house funding, governance

and oversight of medical research), from August 2002 Member and Past

President.

1995-2002 Attending physician, Rheumatology, University Hospital, Basel.

1992-1994 Clinical fellowships in rheumatology, Stadtspital Triemli, Zürich and University

Hospital, Zürich.

1989-1991 Senior research fellow with scholarships from the Swiss Foundation for Medical-

Biological Studies and the New York Chapter of the Arthritis Foundation at the

Department of Rheumatology, Hospital for Special Surgery, Cornell University,

Weill Medical College, New York.

1987-1989 Fellowship with a scholarship of the Swiss Academy of Medical Sciences, Basel,

Division of Rheumatic Diseases, Case Western Reserve University Hospitals,

Cleveland, Ohio.

1984-1987 Residency in internal medicine, Bürgerspital Solothurn. Organization and

conduction of several phase I and II drug trials for pharmaceituical industry.

1983 Residency at the Institute for Clinical Immunology, Inselspital Bern.

5. Teaching experience

2018-2022 Organization and participation in instruction of skills in Internal Medicine for

students of Bachelor in Medicine, ETH Zürich

1996-2022 Organization of continuing medical education for residents/fellows with

participation of practicing specialists in rheumatology according to thePaul Hasler, CV 2nd September 2024 2

requirements of the Swiss Institute for Education and Continuing Medical

Education.

1995-2022 Medical student instruction in clinical skills in Internal Medicine and

Rheumatology, subject-oriented tutorials in Rheumatology, lectures in

Rheumatology and Immunology, University of Basel.

1995-1996 Instruction of Internal Medicine for physiotherapy students, Physiotherapy School,

Basel.

1984-1987 Specification of study catalogue for the School of Nursing, Bürgerspital,

Solothurn, Switzerland.

6. Honors

1994 Boots Swiss Rheumatology Prize

7. Society Memberships

Swiss Medical Association

Medical Association of the Canton of Aargau

Swiss Society for General Internal Medicine

Swiss Society for Rheumatology

Swiss Society for Allergy and Immunology

American College of Rheumatology

European League against Rheumatism (EULAR)

8. Other Functions

Member of the Medical Faculty, University of Basel

Past Lecturer at the Department of Health Sciences and Technology, ETHZ

Past President and Member of the Scientific Committee of the Swiss Society for Rheumatology

Founding and past member of the board of the Swiss Clinical Quality Management in

Rheumatoid Arthritis (SCQM) Foundation

Past Editor, Seminars in Immunopathology, Springer Nature

Grant reviews

Peer reviews

Scientific consultant for pharmaceutical companies

Past Member, Ethics Committee of the Canton of Aargau

9. Publications

9.1. Peer Reviewed Publications

1. Defective cAMP-dependent phosphorylation of intact T lymphocytes in active systemic lupus erythematosus.

Hasler P, Schultz LA, Kammer GM. Proc Natl Acad Sci USA 1990;87:1978-82.

2. cAMP-dependent protein kinase A in chondrocyte cultures: holoenzyme activation, phosphorylation of

cellular proteins, effects of NSAIDs and possible role in proteoglycan synthesis. Malemud CJ., Papay R,

Hasler P, Kammer GM Semin Arthr Rheum 1990:19:10-5 (Suppl).

3. Ist die Kochsalziodierung noch nötig? Supersaxo Z, Selz B, Hasler P, Wespi HJ, Abelin T, Bürgi H. Schweiz

Med Wschr 1991;121:317-23.

4. Ribosomal P proteins P0, P1 and P2 are phosphorylated by casein kinase II at their conserved carboxyl-

termini. Hasler P, Brot N, Weissbach H, Parnassa AP, Elkon KB. J Biol Chem 1991;266:13815-20.

5. Human T lymphocyte cAMP-dependent protein kinase: Subcellular distributions and activity ranges of type I

and Type II isozymes. Hasler P, Moore JJ, Kammer GM. FASEB J. 1992;6:2735-41.

6. The effect of circulating serum factors from patients with systemic lupus erythematosus on protein kinase A

(PKA) activity and PKA-dependent protein phosphorylation in T lymphocytes. Kammer GM, Haqqi TM,

Hasler P, Malemud CJ. Clin Immunol Immunopathol. 1993;67:8-16.

7. Insufficiency fractures of the sacrum: 20 cases and review of the literature. Weber M, Hasler P, Gerber H.

Spine 1993;18:2507-12.

8. The effect of nonsteroidal anti-inflammatory drugs on cAMP-dependent protein kinase phosphorylation in

human chondrocyte cultures. Malemud CJ, Papay RS, Hasler P, Kammer GM. Clin Exp Rheumatol.

1994;12:149-56.

9. The effect of phosphorylation and site-specific mutations of the immunodominant epitope of the ribosomal P

proteins on the binding of anti-P autoantibodies. Hasler P, Blount, Y, Brot N, Weissbach H, Elkon KB. Clin

Immunol Immunopathol. 1994:72:273-79.

10. Vasculitides in hairy-cell leukemia. Hasler P, Kistler H, Gerber H. Semin Arthr Rheum 1995;25:134-42.

11. A woman with panic attacks and double vision who liked cheese. Vogt T, Hasler P. Lancet 1999:354:300.Paul Hasler, CV 2nd September 2024 3

12. Feasibility of the RADAI, a self-administered rheumatoid arthritis activity index. Fransen J., Langenegger T.,

Michel B.A., Stucki G. for the members of the Swiss Clinical Quality Management in Rheumatoid Arthritis.

Rheumatology 2000;39:321-27.

13. Clinical quality management in rheumatoid arthritis: putting theory into practice. Uitz E., Fransen J.,

Langenegger T., Stucki G. for the members of the Swiss Clinical Quality Management in Rheumatoid

Arthritis. Rheumatology 2000;39:542-49.

14. B cell receptor signaling and autoimmunity. Hasler P, Zouali M. FASEB J 2001;15;2085-2098.

15. Der Nachweis von Autoantikörpern gegen extrahierbare nukleäre Antigene (ENA) mittels Line Immunoassay

(LIA) im Vergleich mit dem Enzyme-Linked Immunosorbent Assay (ELISA) in Relation zu anderen

Laborparametern und zur Klinik. Maclachlan D, Vogt P, Rose L, Wu X, Tyndall A, Hasler P. Z Rheumatologie

2002;61:534-44.

16. Posterior tibial tendon dysfunction and MRI-imaging in rheumatoid arthritis. Hasler P, Meier M, Hintermann

B. Rheumatol Int 2002:22:38-40.

17. Subversion of B lymphocyte signaling by infectious agents. Hasler P, Zouali M. Genes and Immunity

2003;4:95-103.

18. Meeting Highlights. Frontiers in Autoimmunity: Fundamental Aspects and Clinical Perspectives. NATO

Advanced Study Institute, Keszthely, Hungary 2002. Hasler P, Zouali M. Expert Opin Ther Targets

2003;7:125-130.

19. Arthritis and interstitial granulomatous dermatitis (Ackerman Syndrome) with pulmonary silicosis. Kroesen S,

Itin P, Hasler P. Semin Arthr Rheum 2003;32:334-40.

20. Serious bacterial infections under anti-TNF therapy. Kroesen S, Widmer A, Tyndall A, Hasler P.

Rheumatology 2003;42:617-21.

21. Efficacy and safety of 4 doses of lumiracoxib versus diclofenac in patients with knee or hip primary

osteoarthritis: A 4-week multicenter, randomized, double-blind, placebo-controlled trial. Schnitzer T, Beier J,

Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Jayawardene S, Sloan VS, Poor G. Arthritis Rheum

2004;51:549-57.

22. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis

factor-alpha treatment. Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, Frei R, Widmer AF. J

Rheumatol. 2005;32:2125-9.

23. Immune receptor signaling, aging and autoimmunity. Hasler P, Zouali M. Cell Immunol 2005;233:102-108.

24. Biological Therapies Directed Against Cells in Autoimmune Disease. Hasler P. Semin Immunopathol

2006;27:443-56.

25. B lymphocytes as therapeutic targets in systemic lupus erythematosus. Hasler P, Zouali M. Expert Opin Ther

Targets 2006;10:803-815.

26. Occurrence of neutrophil extracellular DNA traps (NETs) in pre-eclampsia: a link with elevated levels of cell-

free DNA? Gupta AK, Hasler P, Gebhardt GS, Holzgreve W. Hahn S. Ann N Y Acad Sci 2006;1075:118-22.

27. Occurrence of neutrophil extracellular DNA traps (NETs) in pre-eclampsia: a link with elevated levels of cell-

free DNA? Gupta AK, Hasler P, Gebhardt GS, Holzgreve W, Hahn S. Ann N Y Acad Sci 2006;1075:118-22.

28. Hörverlust nach Myelographie. Schiffer P, Podvinec M, Hasler P. Praxis Schweiz Rundschau Medizin

2006;95:369-73.

29. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in

preeclampsia. Gupta A., Hasler P, Holzgreve W, Gebhardt S, Hahn S. Human Immunol 2006;66:1146-54.

30. Occurrence of neutrophil extracellular traps (NETs) in pre-eclampsia. A link with elevated levels of cell-free

DNA? Gupta A, Hasler P, Gebhardt S, Holzgreve W, Hahn S.. Ann NY Acad Sci 2006;1075:118-22.

31. Chronische, erosive Polyarthritis mit lumbalen Rückenschmerzen und chronisch rezidivierenden

Oberbauchschmerzen. Iseli A., Hüllstrung HD, Hasler P. Schweiz Rundsch Med Prax 2006;95:287-90.

32. Detection of tuberculosis by extensive screening in a patient with rheumatoid arthritis prior to anti-TNF-alpha

therapy. Iseli A, Hüllstrung HD, Rodenhausen S, Widmer FA, Tyndall A, Hasler P. Rheumatology

2006;45:1049-50.

33. Protein microarray platform for the multiplex analysis of biomarkers in human sera. Urbanowska T,

Mangialaio S, Zickler C, Cheevapruk S, Hasler P, Regenass S, Legay F. J Immunol Methods 2006;316:1-7.

34. Complete recovery of visual acuity in two patients with giant cell arteritis. Jaggi GP, Lüthi U, Forrer A, Hasler

P, Killer HE. Swiss Med Wkly 2007;137:265-8.

35. Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Zhong XY, Li Y,

von Mühlenen I, Hristoskova S, Kang A, Tyndall A, Holzgreve W, Hahn S, Hasler P. Clin Chem

2007;53:1609-14.

36. Neutrophil NETs: a novel contributor to preeclampsia-associated placental hypoxia? Gupta AK, Hasler P,

Holzgreve W, Hahn S. Semin Immunopathol 2007;29:163-7.

37. Safety and efficacy of biologics directed against TNF-alpha and CD20 in the therapy of vasculitis and

systemic lupus erythematosus. Walker UA, Hasler Paul Ther Umschau 2008;65:303.

38. Hemophagocytic syndrome in adult-onset Still’s disease (AOSD): A must for biologics? – Case report and

brief review of the literature. Bürgi U, Mendez A, Hasler P, Hüllstrung HD. Rheumatol Int 2012;32:3269.

39. Gupta AK, Joshi MB., Philippova M, Erne P, Hasler P, Hahn S, Resink TJ. Activated endothelial cells induce

neutrophil extracellular traps and are susceptible to NETosis-mediated cell death FEBS Lett 2010;584:3193.

40. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis:

results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. Avouac J, Walker U,

Tyndall A, et al J. Rheumatol 2010;37:1488-501.Paul Hasler, CV 2nd September 2024 4

41. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research

group database. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O,

Riemekasten G, Valentini G, Müller-Ladner U; EUSTAR Co-authors. Ann Rheum Dis 2012;71:1355.

42. HORIZON Pivotal Fracture Group Once-yearly zoledronic acid and days of disability, bed rest, and back

pain: randomized, controlled HORIZON Pivotal Fracture Trial.Cauley JA, Black D, Boonen S, Cummings SR,

Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; J Bone Miner Res 2011;26:984.

43. Mononeuritis multiplex under the TNF-alpha inhibitor infliximab. Bandelow N, Wiederkehr M, Hasler P. Praxis

2011;100:241-3.

44. Refractory neuro-Behcet treated by tocilizumab: Case report. Urbaniak P, Hasler P, Kretzschmar S. Clin Exp

Rheumatol 2012;30 Suppl 72:S73-5.

45. Reactive arthritis. Ryser C, Hasler P. Praxis 2010;99:1317-26.

46. Use of abatacept in rheumatoid arthritis. von Kempis J, Dudler J, Hasler P, Kyburz D, Tyndall A, Zufferey P,

Villiger PM. Swiss Med Wkly 2012; 11;142.

47. Neutrophil NETs in reproduction: from infertility to preeclampsia and the possibility of fetal loss.Hahn S,

Giaglis S, Hoesli I, Hasler P. Front Immunol 2012;3:362.

48. Fractures associated with diminished bone density, hypercalciuria and osteolysis. Is the diagnosis

osteoporosis or a syndrome? Neuwirth A, Geeser A, Hasler P. Praxis 2012;101:413.

49. Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology. Hahn

S, Giaglis S, Chowdhury CS, Hösli I, Hasler P. Semin Immunopathol 2013;35:439

50. Special issue on neutrophils. Hasler P, Hahn S. Semin Immunopathol. 2013;35:375-6.

51. Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology. Hahn

S, Giaglis S, Chowdhury CS, Hösli I, Hasler P. Semin Immunopathol 2013;35:439.

52. Cell-free nucleic acids in (maternal) blood: any relevance to (reproductive) immunologists? Hahn S, Giaglis

S, Buser A, Hoesli I, Lapaire O, Hasler P. J Reprod Immunol 2014;pii: S0165-0378.

53. Biological agents in monotherapy for the treatment of rheumatoid arthritis. Gabay C., Hasler P, Kyburz D, So

A., Villiger P, von Kempis J, Walker U. Swiss Med Wkly 2014;144:w13950.

54. Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular

calcium pools and Is modulated by cyclosporine A. Gupta AK, Giaglis S, Hasler P, Hahn S. PLoS ONE

2014;9(5): e97088. doi:10.1371/journal.pone.0097088.

55. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: Analysis of underlying signal

transduction pathways and potential diagnostic utility. Sur Chowdhury C, Giaglis S, Walker UA, Buser A,

Hahn S, Hasler P. Arthritis Res Ther 2014;doi:10.1186/ar4579.

56. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective

study. Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, Caramaschi P, Ananieva

LP, Matucci-Cerinic M, Czirjak L, Denton C, Ladner UM, Allanore Y; the EUSTAR collaborators. Ann Rheum

Dis 2014 doi:10.1136/annrheumdis-2014-205295.

57. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse

cutaneous systemic sclerosis: a randomized clinical trial. van Laar JM, Farge D, Sont JK, Naraghi K,

Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M,

Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM,

Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF,

Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich

É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A;

EBMT/EULAR Scleroderma Study Group. JAMA 2014 Jun 25;311:2490-8.

58. The dermatologist’s role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to

improve collaboration with rheumatologists. Boehncke W-H, Anliker MD, Conrad C, Dudler J, Hasler F,

Hasler P, Häusermann P, Kyburz D, Laffitte E, Michel BA, Möller B, Navarini AA, Villiger PM, Yawalkar N,

Gabay C. Dermatology 2015;230:75.T

59. he advent of biosimilars: challenges and risks. Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P.

Swiss Med Wkly 2014 Jul 1;144:w13980.

60. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Mihai C, Landewé R, van

der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Czirják L,

Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, Matucci-Cerinic M; EUSTAR co-

authors. Ann Rheum Dis 2016 Apr;75(4):681-6.

61. Elevated Levels of Total Cell-Free DNA in Maternal Serum Samples Arise from the Generation of Neutrophil

Extracellular Traps. Sur Chowdhury C, Hahn S, Hasler P, Hoesli I, Lapaire O, Giaglis S. Fetal Diagn Ther

2016;40:263-267.

62. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-

year longitudinal study from the EUSTAR database. Wirz EG, Jaeger VK, Allanore Y, Riemekasten G,

Hachulla E, Distler O, Airò P, Carreira PE, Tikly M, Vettori S, Balbir Gurman A, Damjanov N, Müller-Ladner

U, Distler J, Li M, Häusermann P, Walker UA; EUSTAR coauthors. Ann Rheum Dis 2016;75:1285-92.

63. The “NET Outcome": Are neutrophil extracellular traps of any relevance to the pathophysiology of

autoimmune disorders in childhood? Giaglis S, Hahn S, Hasler P. Front Pediatr 2016 Sep 13;4:97.

64. Neutrophil extracellular traps in health and disease. Hasler P, Giaglis S, Hahn S. Swiss Med Wkly 2016 Oct

10;146:w14352.Paul Hasler, CV 2nd September 2024 5

65. Surgical versus conservative treatment for lumbar disc herniation: A Prospective Cohort Study. Marinella

Gugliotta, Bruno R. da Costa, Essam Dabis, Robert Theiler, Peter Jüni, Stephan Reichenbach, Hans

Landolt, Paul Hasler. BMJ Open 2016 Dec 21;6(12):e012938.

66. Multimodal regulation of NET formation in pregnancy: Progesterone antagonizes the pro-NETotic effect of

estrogen and G-CSF. Giaglis S, Stoikou M, Sur Chowdhury C, Schaefer G, Grimolizzi F, Rossi SW, Hoesli

IM, Lapaire O, Hasler P, Hahn S. Front Immunol 2016 Dec 5;7:565.

67. An international survey on non-invasive techniques to assess the microcirculation in patients with Raynaud's

phenomenon (SUNSHINE survey). Ingegnoli F, Ughi N, Dinsdale G, Orenti A, Boracchi P, Allanore Y et al;

EULAR Study Group on Microcirculation in Rheumatic Diseases. Rheumatol Int 2017;37:1879-1890.

68. Gestational diabetes mellitus Is associated with altered neutrophil activity. Stoikou M, Grimolizzi F, Giaglis S,

Schäfer G, van Breda SV, Hoesli IM, Lapaire O, Huhn EA, Hasler P, Rossi SW, Hahn S. Front Immunol

2017;8:702.

69. Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies. Hasler P, Gabay C.

Semin Immunopathol 2017;39:339-341.

70. Update of EULAR recommendations for the treatment of systemic sclerosis. Kowal-Bielecka O, Fransen J,

Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del

Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N,

Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith

V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U;

EUSTAR Coauthors. Ann Rheum Dis 2017;76:1327-1339.

71. A multidisciplinary DELPHI-consensus-based checklist to define clinical documentation tools both for routine

and research purposes. Veraar C, Schirmer M, Hasler P. Health Serv Res Manag Epidemiol. 2018

6;5:2333392817754161

72. Markers of Neutrophil Extracellular Traps Predict Adverse Outcome in Community-Acquired Pneumonia

Secondary Analysis of a Randomised Controlled Trial. Ebrahimi F, Giaglis S, Hahn S, Blum CA,

Baumgartner C, Kutz A, van Breda SV, Mueller B, Schütz P, Christ-Crain M, Hasler P. Eur Respir J. 2018 pii:

1701389.

73. Excessive Neutrophil Activity in Gestational Diabetes Mellitus: Could It Contribute to the Development of

Preeclampsia? Vokalova L, van Breda SV, Ye XL, Huhn EA, Than NG, Hasler P, Lapaire O, Hoesli I, Rossi

SW, Hahn S. Front Endocrinol (Lausanne) 2018 Sep 21;9: e0208275.

74. The role of neutrophil activation in determining the outcome of pregnancy and modulation by hormones

and/or cytokines. Hahn S, Hasler P, Vokalova L, van Breda SV, Lapaire O, Than GN, Hoesli I, Rossi SW.

Clin Exp Immunol 2019 doi: 10.1111/cei.13278.

75. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases – a

prospective multi-centre cohort study. Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A,

Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ,

Siegrist CA, Villiger PM, Walker UA, Hatz C. Rheumatology (Oxford). 2019 Mar 15. pii: kez045.

76. Feto-Maternal Microchimerism: The Pre-eclampsia Conundrum. Hahn S, Hasler P, Vokalova L, van Breda

SV, Than NG , Hoesli IM, Lapaire O, Rossi SW. Front Immunol 2019 doi.org/10.3389.

77. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective

cohort study. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME,

Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E,

Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold

AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C,

Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR

network. Ann Rheum Dis 2019 pii: annrheumdis-2018-214816

78. Computational methodologies for the quantification of neutrophil extracellular traps. van Breda SV, Vokalova

L, Neugebauer C, Rossi SW, Hahn S, Hasler P. Front Immunol. 2019 doi.org/10.3389/fimmu.2019.01562

79. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-

world data from the St. Gallen and Aarau cohorts. Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M,

Souza A, Hasler P, Rubbert-Roth A, Schulze-Koops H, von Kempis J. J Clin Med. 2019;8:1548:

doi:10.3390/jcm8101548

80. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.

Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW,

Walker UA, Hatz C, Bühler S. Vaccine 2020;38:3610-3617.

81. Pain relief and gain of function from low dose radiotherapy for epicondylitis, finger polyarthritis and plantar

fasciitis. Rogers S, Eberle B, Vogt D, Meier E, Moser L, Gomez S, Desborough S, Riesterer O, Takacs I,

Hasler P, Bodis S. Front. Med. doi: 10.3389/fmed.2020.00195.

82. Longterm immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.

Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW,

Walker UA, Hatz C, Bühler S: Vaccine 2020, 38(19):3610-3617.

83. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action

and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. Finckh A,

Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L,

Müller R, Hasler P, Zufferey P: RMD Open 2020, 6(1).

84. Rheumatoid Arthritis from Pathogenesis to Therapeutic Strategies. Mueller RB, Hasler P: J Clin Med 2020,

9.Paul Hasler, CV 2nd September 2024 6

85. Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to

controls: A multi-centre, observational study. Schmid N, Ciurea A, Gabay C, Hasler P, Fehr J, Muller R,

Villiger P, Walker U, Hatz C, Buhler S: Travel Med Infect Dis 2020, 38:101818.

86. Rheumatoid Arthritis from Pathogenesis to Therapeutic Strategies. Mueller RB, Hasler P. J Clin Med 2020,

9.

87. Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to

controls: A multi-centre, observational study. Schmid N, Ciurea A, Gabay C, Hasler P, Fehr J, Muller R,

Villiger P, Walker U, Hatz C, Buhler S. Travel Med Infect Dis 2020, 38:101818.

88. Prospective Evaluation of Changes in Pain Levels, Quality of Life and Functionality After Low Dose

Radiotherapy for Epicondylitis, Plantar Fasciitis, and Finger Osteoarthritis. Rogers S, Eberle B, Vogt DR,

Meier E, Moser L, Gomez Ordonez S, Desborough S, Riesterer O, Takacs I, Hasler P, Bodis S. Front Med

(Lausanne) 2020, 7:195.

89. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action

and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. Finckh A,

Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, et

al. RMD Open 2020, 6.

90. Current practice of transitional care for adolescents and young adults in Swiss paediatric and adult

rheumatology centres.Berben L, Sigg N, Daly ML, Bachmann S, Baer W, Berthet G, Bolt I, Dan D, Enderlin

Steiger S, Frohlich J, Hasler P, Hofer M, Huemer C, Kaiser D, Marcoli N, Palmer Sarott S, Rottlander Y,

Schmid G, Soennichsen C, Strahm Furler L, Vanoni F, Wildi L, Daikeler T, Woerner A. Swiss Med Wkly

2021, 151:w30046.

91. Circulatory Neutrophils Exhibit Enhanced Neutrophil Extracellular Trap Formation in Early Puerperium: NETs

at the Nexus of Thrombosis and Immunity. Giaglis S, Sur Chowdhury C, van Breda SV, Stoikou M, Tiaden

AN, Daoudlarian D, Schaefer G, Buser A, Walker UA, Lapaire O, Hoesli I, Hasler P, Hahn S. Int J Mol Sci

2021, 22(24).

92. The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. Hernandez

J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribi C, Villiger P, Vlachoyiannopoulos P, Vacca A, Garzanova L,

Giollo A, Rosato E, Kotter I, Carreira PE, Doria A, Henes J, Muller-Ladner U, Smith V, Distler O. The Eustar

Consortium. Swiss Med Wkly 2021, 151:w20528.

93. Effect of Anti-Inflammatory Diets on Pain in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.

Schoenenberger KA, Schupfer AC, Gloy VL, Hasler P, Stanga Z, Kaegi-Braun N, Reber E. Nutrients 2021,

13(12).

94. Successful Treatment of Rheumatoid Meningitis Associated with a decrease of ACPA Antibody Index. Rubeli

S, Conen C, Diepers M, Bernasconi L, Hasler P, Müller R. J Clin Rheumatol 2022;28:e667.

95. Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with

inflammatory rheumatic diseases and healthy controls. Mischlinger J, Jaeger VK, Ciurea A, Gabay C, Hasler

P, Mueller RB, Siegrist CA, Villiger P, Walker UA, Hatz C, Bühler S. Vaccine. 2022;40:4897-4904.

96. Can the complex, multifactorial gait disorder of a 28-year-old patient ben significantly improved? Truschkat

A, Poller M, Berli M, Hasler P. Praxis 2022, in press.

97. Serious infection risk of tofacitinib compared to biologics inpatients with rheumatoid arthritis treated in routine

clinical care. Riek M, Scherer A, Möller B, Ciurea A, von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von

Kempis J, Mueller RB, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Sci Report

2023;13:17776.

98. Therapeutic management of systemic sclerosis patients – an analysis from the Swiss cohort. Windirsch K,

Jordan S, Becker MO, Bruni C, Dobrota R, Elhai M, Garaiman IA, Mihai CM, Iudici M, Hasler P, Ribi C,

Maurer B, Gabrielli A, Hoffmann-Vold AM, Distler O. Swiss Med Wkly 2024;154:3630.

1. r P. (2003). Rheumatology 43:116.